AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26047719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol reactivity to the TSST-M
Number of subjects: 75
Study 26047719 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary alpha-amylase levels
Number of subjects: 75
Study 26047719 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective stress ratings for the task
Number of subjects: 75
Study 23115341 — intervention group
Group type: EXPERIMENTAL
Intervention: No change condition (yellow tablet 'Betaprol')
Number of subjects: 62
Study 23115341 — intervention group
Group type: COMPARATOR
Intervention: Generic change condition (white tablet 'Generic')
Number of subjects: 62
Study 23115341 — intervention group
Group type: COMPARATOR
Intervention: Branded change condition (white tablet 'Novaprol')
Number of subjects: 62
Study 21147420 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect tri-planar MFR technique (3 min)
Number of subjects: 31
Study 21147420 — intervention group
Group type: COMPARATOR
Intervention: Hot pack application (20 min)
Number of subjects: 31
Study 19072483 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V Everolimus-Eluting Coronary Stent System
Number of subjects: 2000
Study 19072483 — intervention group
Group type: COMPARATOR
Intervention: CYPHER Plus
Number of subjects: 2000
Study 15611456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasojejunal tube placement (NJT group)
Number of subjects: 237
Study 15611456 — intervention group
Group type: COMPARATOR
Intervention: No nasojejunal tube placement (no-NJT group)
Number of subjects: 237
Study 10422616 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity exercise
Number of subjects: 80
Study 10422616 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 80
Study 10422616 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 80
Study 7488565 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaffolded instruction
Number of subjects: 41
Study 7488565 — intervention group
Group type: COMPARATOR
Intervention: Didactic instruction
Number of subjects: 41
Study 2272819 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help relaxation training
Number of subjects: 48
Study 2272819 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormezanone (muscle relaxant)
Number of subjects: 48
Study 2272819 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 48
Study 540525 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (2.4 g per day)
Number of subjects: 109
Study 540525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 31125823 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg tid for 14 days
Number of subjects: 39
Study 27506309 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of poikilocapnic normobaric hypoxia
Number of subjects: 0
Study 27506309 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 hours of poikilocapnic normobaric hypoxia
Number of subjects: 0
Study 27506309 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic challenge (5% CO2)
Number of subjects: 0
Study 26948962 — intervention group
Group type: EXPERIMENTAL
Intervention: aerobic dance
Number of subjects: 120
Study 25390870 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading protocol (G1)
Number of subjects: 36
Study 25390870 — intervention group
Group type: COMPARATOR
Intervention: Early loading protocol (G2)
Number of subjects: 36
Study 22559251 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity information program (Spanish-language video)
Number of subjects: 600
Study 22559251 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity program (video + 'promotora' intervention)
Number of subjects: 600
Study 22559251 — intervention group
Group type: COMPARATOR
Intervention: Control arm (usual care)
Number of subjects: 600
Study 22559251 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator program
Number of subjects: 600
Study 22559251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness evaluation of intervention programs
Number of subjects: 600
Study 20073212 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound salvia injection (20 mL in 10% glucose 500 mL for intravenous dripping once a day) and UDCA (15 mg, thrice daily by oral taken)
Number of subjects: 128
Study 20073212 — intervention group
Group type: COMPARATOR
Intervention: UDCA alone
Number of subjects: 128
Study 17526181 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp-acupuncture drawing method (SADM)
Number of subjects: 93
Study 17526181 — intervention group
Group type: COMPARATOR
Intervention: Scalp-acupuncture twirling method (SATM)
Number of subjects: 93
Study 17526181 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control group II)
Number of subjects: 93
Study 15259516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microg/kg)
Number of subjects: 24
Study 15259516 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (1 mg/kg)
Number of subjects: 24
Study 11211004 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-controlled multiple views
Number of subjects: 146
Study 11211004 — intervention group
Group type: EXPERIMENTAL
Intervention: High spatial ability of the student
Number of subjects: 146
Study 11211004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed examination of an object from multiple different perspectives
Number of subjects: 146
Study 9526894 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich diet (T-FAT)
Number of subjects: 15
Study 9526894 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich diet (T-CHO)
Number of subjects: 15
Study 8018611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin and metronidazole for five days
Number of subjects: 81
Study 8018611 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 81
Study 2591060 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (250 micrograms/day in 4 divided s.c. injections for 1 month, followed by continuous s.c. infusions for another month, then 200 micrograms three times daily as s.c. injections)
Number of subjects: 9
Study 2591060 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide treatment
Number of subjects: 9
Study 31833226 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment (1 day and 4 days)
Number of subjects: 10
Study 31833226 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment (4 days)
Number of subjects: 10
Study 31833226 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 10
Study 28291237 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-L split-dose polyethylene-glycol (PEG) regimen
Number of subjects: 256
Study 28291237 — intervention group
Group type: COMPARATOR
Intervention: 2-L split-dose PEG plus ascorbic acid (PEG+Asc) regimen
Number of subjects: 256
Study 25881037 — intervention group
Group type: EXPERIMENTAL
Intervention: Samata intervention
Number of subjects: 2100
Study 25881037 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2100
Study 22951028 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise training program that includes perturbation exercises (WEP) for 12 weeks.
Number of subjects: 36
Study 22951028 — intervention group
Group type: COMPARATOR
Intervention: No intervention for the first 12 weeks (Control Group B).
Number of subjects: 36
Study 22951028 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise training program that includes perturbation exercises (WEP) for 12 weeks (Control Group B).
Number of subjects: 36
Study 21866432 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1 mg·kg(‐1) iv
Number of subjects: 120
Study 21866432 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 2 mg·kg(‐1) iv
Number of subjects: 120
Study 21866432 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control group)
Number of subjects: 120
Study 19897689 — intervention group
Group type: EXPERIMENTAL
Intervention: Management based on symptoms
Number of subjects: 46
Study 19897689 — intervention group
Group type: COMPARATOR
Intervention: Speculum examination and wet mount (Control)
Number of subjects: 46
Study 17518165 — intervention group
Group type: EXPERIMENTAL
Intervention: Victorian ANF nurse members
Number of subjects: 574
Study 15358014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary brachytherapy (ICB)
Number of subjects: 92
Study 15358014 — intervention group
Group type: COMPARATOR
Intervention: No radiation (Control)
Number of subjects: 92
Study 11777191 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate liquid suspension 800 mg/day
Number of subjects: 85
Study 11777191 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol tablets 2.5 mg b.i.d.
Number of subjects: 85
Study 11777191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of megestrol acetate and dronabinol
Number of subjects: 85
Study 11777191 — intervention group
Group type: EXPERIMENTAL
Intervention: Alterations in appetite (reported by patients)
Number of subjects: 85
Study 11777191 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in serum IL-6
Number of subjects: 85
Study 9834804 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane/N2O (Group 1)
Number of subjects: 20
Study 9834804 — intervention group
Group type: COMPARATOR
Intervention: Desflurane alone (Group 2)
Number of subjects: 20
Study 9834804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 8027215 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (4 months treatment)
Number of subjects: 86
Study 2917597 — intervention group
Group type: EXPERIMENTAL
Intervention: Viqualine 75 mg bd
Number of subjects: 16
Study 2917597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (blood alcohol concentrations of 17-22 mmol.l-1)
Number of subjects: 16
Study 2917597 — intervention group
Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 16
Study 2917597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2917597 — intervention group
Group type: EXPERIMENTAL
Intervention: Viqualine
Number of subjects: 16
Study 4149613 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 4149613 — intervention group
Group type: EXPERIMENTAL
Intervention: Prindolol
Number of subjects: 0
Study 4149613 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and other beta-blockers
Number of subjects: 0
Study 30683074 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting state functional connectivity analysis in adults with ADHD
Number of subjects: 38
Study 30683074 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related analysis
Number of subjects: 38
Study 28057361 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg (weeks 0 and 4, then every 8 weeks)
Number of subjects: 992
Study 28057361 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg
Number of subjects: 992
Study 28057361 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab maintenance
Number of subjects: 992
Study 28057361 — intervention group
Group type: COMPARATOR
Intervention: adalimumab (80 mg week 0, then 40 mg week 1, and every 2 weeks through week 23)
Number of subjects: 992
Study 28057361 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 992
Study 28057361 — intervention group
Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 992
Study 25325371 — intervention group
Group type: EXPERIMENTAL
Intervention: Head of Bed (HOB) elevation to 15°
Number of subjects: 71
Study 25325371 — intervention group
Group type: COMPARATOR
Intervention: Standard care with HOB completely flat
Number of subjects: 71
Study 23356246 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-focused lifestyle coaching delivered by telephone over a one-year period
Number of subjects: 2840
Study 23356246 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 2840
Study 21526412 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence behaviour measures (intentional nonadherence associated with self-regulation)
Number of subjects: 1426
Study 21526412 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence behaviour measures (intentional nonadherence associated with effect concerns)
Number of subjects: 1426
Study 21526412 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence behaviour measures (non-intentional non-adherence)
Number of subjects: 1426
Study 21526412 — intervention group
Group type: EXPERIMENTAL
Intervention: Established measures of non-adherence
Number of subjects: 1426
Study 21526412 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy measures
Number of subjects: 1426
Study 18266550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 32
Study 18266550 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 32
Study 16505284 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic Inflammatory and Nutritional Index (PINI) assessment based on albumin, alpha1‐acid glycoprotein, C‐reactive protein, and prealbumin measurements.
Number of subjects: 0
Study 16505284 — intervention group
Group type: EXPERIMENTAL
Intervention: PINI assessment
Number of subjects: 0
Study 15253125 — intervention group
Group type: COMPARATOR
Intervention: Healthy group (N=25)
Number of subjects: 41
Study 15253125 — intervention group
Group type: EXPERIMENTAL
Intervention: HIE group (N=16)
Number of subjects: 41
Study 15253125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 11403980 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg DHEA daily for 13 weeks
Number of subjects: 46
Study 11403980 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 13 weeks
Number of subjects: 46
Study 9409946 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolones (ciprofloxacin, 500 mg/12 h per os; pefloxacin, 200 mg/12 h intravenous)
Number of subjects: 39
Study 9409946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracyclines (rolitetracycline, 275 mg/12 h intravenous)
Number of subjects: 39
Study 9409946 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study 8323891 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl (1.0 mcg.kg‐1) followed by continuous infusion of fentanyl (1.0 mcg.kg‐1h‐1)
Number of subjects: 25
Study 8323891 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (1.0 mcg.kg‐1) followed by continuous infusion of fentanyl (0.5 mcg.kg‐1 x h‐1) and clonidine (0.3 mcg.kg‐1 x h‐1)
Number of subjects: 25
Study 8323891 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl + clonidine
Number of subjects: 25
Study 3095503 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin with 3% saline
Number of subjects: 50
Study 3095503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with mannitol diuresis
Number of subjects: 50
Study 3095503 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug combination of methotrexate (MTX), 5-fluorouracil (5-FU), and cisplatin
Number of subjects: 50
Study 3095503 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 50
Study 29298124 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 μg twice/day
Number of subjects: 50
Study 29298124 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 μg twice/day
Number of subjects: 50
Study 29298124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27664217 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of etonogestrel releasing implant (inserted 1 hour after mifepristone intake)
Number of subjects: 551
Study 27664217 — intervention group
Group type: COMPARATOR
Intervention: Routine insertion of etonogestrel releasing implant (inserted at follow-up 2-4 weeks later)
Number of subjects: 551
Study 27664217 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of etonogestrel releasing implant
Number of subjects: 551
Study 27664217 — intervention group
Group type: COMPARATOR
Intervention: Routine insertion of etonogestrel releasing implant
Number of subjects: 551
Study 23995299 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 23995299 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 23995299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23995299 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study 22935338 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (Q) 1095 mg
Number of subjects: 12
Study 22935338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 20863929 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (S75-R25)
Number of subjects: 49
Study 20863929 — intervention group
Group type: COMPARATOR
Intervention: 0.20% ropivacaine
Number of subjects: 49
Study 19011774 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 ml (6 mg) of 0.5% hyperbaric bupivacaine with 0.16 mg of morphine (group BM)
Number of subjects: 60
Study 19011774 — intervention group
Group type: COMPARATOR
Intervention: 1.2 ml (6 mg) of 0.5% hyperbaric bupivacaine (group B)
Number of subjects: 60
Study 16164158 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg once daily
Number of subjects: 70
Study 16164158 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 70
Study 14503673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilots
Number of subjects: 19
Study 14503673 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 19
Study 10984265 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide LAR
Number of subjects: 0
Study 10984265 — intervention group
Group type: EXPERIMENTAL
Intervention: lanreotide
Number of subjects: 0
Study 10984265 — intervention group
Group type: COMPARATOR
Intervention: subcutaneous octreotide
Number of subjects: 0
Study 9538650 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial signal-averaged electrocardiogram (ASAECG) parameters
Number of subjects: 53
Study 9538650 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria for identification of PAF
Number of subjects: 53
Study 9538650 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without PAF)
Number of subjects: 53
Study 8251842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin-ergometrine
Number of subjects: 3497
Study 8251842 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 3497
Study 3099490 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally applied nitroglycerin (TDS) 5.0 mg in 24 hours
Number of subjects: 12
Study 3099490 — intervention group
Group type: COMPARATOR
Intervention: Sustained release nitroglycerin capsules (NTR) 2.5 mg
Number of subjects: 12
Study 3099490 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally applied nitroglycerin (TDS) after 3 months
Number of subjects: 12
Study 29301785 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Lp(a) levels
Number of subjects: 152
Study 29301785 — intervention group
Group type: EXPERIMENTAL
Intervention: On-study Lp(a) levels
Number of subjects: 152
Study 29301785 — intervention group
Group type: COMPARATOR
Intervention: Intensive lipid therapy (LDL-C <70 mg/dL)
Number of subjects: 152
Study 26921488 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline concentrations of unacylated ghrelin
Number of subjects: 0
Study 26921488 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline total ghrelin in females
Number of subjects: 0
Study 26921488 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin:ghrelin ratio in females
Number of subjects: 0
Study 26921488 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline concentrations of leptin, adiponectin, and ghrelin
Number of subjects: 0
Study 26921488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of acylated:unacylated ghrelin
Number of subjects: 0
Study 24593225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) 100 cc, 0.7 mM polyphenols, three times a week for one year
Number of subjects: 101
Study 24593225 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 101
Study 21751770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sign Chi Do (SCD) exercise intervention for 12 weeks
Number of subjects: 67
Study 21751770 — intervention group
Group type: COMPARATOR
Intervention: Minimal education control group
Number of subjects: 67
Study 20216073 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Healthware intervention (web-based tool for recording family medical history)
Number of subjects: 2330
Study 20216073 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Healthware intervention
Number of subjects: 2330
Study 20216073 — intervention group
Group type: COMPARATOR
Intervention: Baseline perceptions (before Family Healthware intervention)
Number of subjects: 2330
Study 18925346 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo + medical management
Number of subjects: 466
Study 18925346 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized behavioral therapy + placebo + medical management
Number of subjects: 466
Study 18925346 — intervention group
Group type: COMPARATOR
Intervention: Specialized behavioral therapy alone
Number of subjects: 466
Study 15748120 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps exercise group
Number of subjects: 103
Study 15748120 — intervention group
Group type: COMPARATOR
Intervention: No quadriceps exercise group
Number of subjects: 103
Study 12638641 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT-selective pharmacotherapy
Number of subjects: 0
Study 12638641 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9827783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ardeparin with a 2‐day hospitalization
Number of subjects: 80
Study 9827783 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin sodium with a 5‐day hospitalization
Number of subjects: 80
Study 9827783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ardeparin
Number of subjects: 80
Study 9827783 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 80